Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Penpulimab, Anlotinib, and Chemotherapy as Neoadjuvant Therapy for Locally Advanced Gastric Cancer
NCT05385900Unknown
- Sponsor
- Xijing Hospital
- Start
- Jun 2022
- Primary completion
- Jun 2023
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
01
Overview
Open-label, single-arm trial of penpulimab and anlotinib in gastric cancer (GC), sponsored by Xijing Hospital. Primary endpoint: Pathological Complete Response at 12 months. Status: unknown.
02
Drugs
penpulimabanlotinib
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT05385900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05385900.